Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in Parkinson's Disease
NCT06773962Phase 2Active, not recruiting
- Sponsor
- TrueBinding Inc.
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing TB006 with Placebo (2 arms). Primary endpoints: Parkinson's Disease Rating Scale at 28 weeks, Adverse Events at 28 weeks and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
TB006
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06773962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773962.